Search

Your search keyword '"Golovchenko, O"' showing total 142 results

Search Constraints

Start Over You searched for: Author "Golovchenko, O" Remove constraint Author: "Golovchenko, O"
142 results on '"Golovchenko, O"'

Search Results

2. Congenital heart disease in the ESC EORP Registry of Pregnancy and Cardiac disease (ROPAC)

3. Synthesis and properties of methanesulfonyl derivatives of diethyl esters of 5-(hydroxyalkylamino)-1,3-oxazol-4-yl-phosphonic acids.

4. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis

5. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

6. Clinical and Genetic Characteristics of Preeclampsia

7. Management of Efficiency and Competitiveness of Enterprises

13. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

16. Исследование острой токсичности производного 1,3-оксазол-4-ил-фосфоновой кислоты при внутрибрюшинном введении

17. Determination of Thermodynamic Characteristics of Phase-stabilized Ammonium Nitrate-Based High-energy Solid Combustible Materials.

18. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

19. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

20. CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn's disease : Data from the CALM study

21. Clinical and Genetic Characteristics of Preeclampsia.

25. P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn’s disease: Data from the CALM study

27. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

28. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

29. Evolocumab and clinical outcomes in patients with cardiovascular disease

30. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial

31. Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease : long-term data from CALM

32. Биофармацевтическое исследование взаимодействия доксициклина с минеральными водами и напитками «in vitro»

33. Порівняння хроматографічних методів аналізу в тонкому шарі сорбенту при проведенні ідентифікації фамотидину у таблетках

34. OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM

35. Methods of Reducing the Front Performance Flame at the Underground Mines Works

42. Розробка спектрофотометричної методики кількісного визначення метронідазолу в капсулах

43. The biopharmaceutical study of doxycycline interaction with mineral waters and soft drinks in vitro

45. Розробка спектрофотометричної методики кількісного визначення метронідазолу в капсулах

47. Improvement to primary documentation on account of the housing fund

Catalog

Books, media, physical & digital resources